Traduction de «incremental benefits have been observed » (Néerlandais → Français) :

Incremental benefits have been observed with indacaterol in escalating doses from 75 mcg up to 300 mcg, with higher doses showing increasing benefit for patients, particularly those with more severe disease.
Une augmentation du dosage de 75 mcg à 300 mcg s’est traduite par une progression des bénéfices pour les malades, les doses plus élevées profitant plus à ces derniers, en particulier, à ceux qui souffrent des formes plus sévères de la maladie.

Gender-related differences have also been observed in the form the depression can take in so far as men seek less medical help than women do (who, as a result of their role as a mother and a cultural “predisposition” to express what they feel, are more likely to call on doctors); depression in males is therefore more difficult to detect.
On a également pu observer des différences dans la forme que peut revêtir la dépression en fonction du sexe dans la mesure où les hommes sollicitent moins l’aide du monde médical que les femmes (plus enclines à faire appel aux médecins, par leur rôle de mère, et une « prédisposition » culturelle à formuler ce qu’elles ressentent); la dépression chez le sexe masculin est donc plus difficile à déceler.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Also supporting the broad expansion have been landmark data first presented in 2008, and published in early 2009 in “The New England Journal of Medicine,” that showed the significant anti-cancer benefit of Zometa in reducing the risk of cancer recurrence or death in premenopausal women with hormone-sensitive, earlystage breast cancer.
Cette large progression a été soutenue par de nouveaux résultats d’une étude pivot présentés initialement en 2008 et publiés début 2009 dans «The New England Journal of Medicine» faisant état des bénéfices anticancer importants du Zometa dans le risque de récidive ou de décès chez les femmes préménopausées atteintes d’un cancer du sein hormono-dépendant précoce.

The recommendations made in this report are based on the available epidemiological data, the main observations that have been made with regard to the problem and an inventory of the actions already put in place in Belgium.
Les recommandations émises découlent des données épidémiologiques disponibles, des principaux constats établis par rapport au problème et d’un inventaire d’actions déjà mises en place en Belgique.

Finally, the EFSA observes that there is unlikely to be any interaction between glucuronolactone and caffeine, taurine, alcohol or the effects of physical effort. Yet, it points out that a number of potential interactions between taurine and caffeine have not been examined (EFSA, 2009).
Enfin, l’EFSA signale qu’il est improbable que la glucuronolactone présente une quelconque interaction avec la caféine, la taurine, l’alcool ou les effets de l’exercice mais signale néanmoins qu’un certain nombre d’interactions possibles entre la taurine et la caféine n’ont pas été étudiées (EFSA, 2009).

No major ultrasound 17 technical advances have been made in order to reduce the inter-observer variability of the technique strictly linked to opertaor's experience.
No major ultrasound 34 technical advances have been made in order to reduce the inter-observer variability of the technique strictly linked to opertaor's experience.